roxin was studied with three commercial kits, two of which (Clinical Assays and Damon Diagnostics) gave essentially the same values as did equilibrium dialysis. The third (Amersham International) gave falsely high results because the 1251-labeled thyroxin derivative used in the kit was bound by the autoantibody.
It is well established that circulating autoantibodies to thyroid hormones are found in various thyroid disorders (
1).
Their presence is usually suspected when inappropriate values are obtained for serum thyroxin (T4) or triiodothyronine (T3) by radioimmunoassay (RIA).
Although
RIAs are now available for estimating free T4 (2) (3) (4) (5) , the effect of these circulating antibodies on values obtained for free hormone has not been clarified.
We describe a patient with Graves' disease associated with a circulating anti-T4 autoantibody in whom the effect of this antibody on free T4 RIA was investigated.
Case Report
A 50-year-old man had been in good health until November 1971, when he became aware of palpitation and anterior neck swelling. He was diagnosed as having Graves' disease and was treated with methimazole. In May 1977 he underwent subtotal gastrectomy for gastric ulcer. In September 1977 he was referred to the Kyoto University Hospital for further control of thyrotoxicosis.
On examination, his skin was warm and moist. Tachycardia, fine tremor, and a large diffuse goiter (estimated weight, 80 g) were noted. Exophthalmos was not present.
The clinical impression that the patient was still thyrotoxic was confirmed by laboratory data, as shown below in 
Materials and Methods

Assay of hormones.
Total T4 and T3 concentrations were determined in unextracted serum by RIA with use of polyethylene glycol (Dainabot Radioisotope Labs., Minato-ku, Tokyo 105). Total T4 in serum was also determined by the competitive protein binding assay, with use of the "Tetrasorb" kit (Dainabot). T3 uptake was determined with the "Triobead" kit (Dainabot). The free thyroxin index was calculated by dividing the product of the total T4 (by competitive protein binding) and T3 uptake by 100. We measured serum thyrotropin with the double antibody RIA, using a commercial kit (Daiichi Radioisotope Labs., Chuo-ku, Tokyo 103). Free T4 was estimated by equilibrium dialysis (6) with purification of the tracer by preliminary dialysis in the presence of serum proteins (7) and with use of trichioroacetic acid precipitation (8) . The calculated free T4 concentration was the product of the percent free T4 and total T4 concentration The binding of to the serum was studied by using aT4 RIA kit without the addition of the provided anti-T4 serum. We incubated 25 1sLof the serum, 100 1sLof '251-T4(specific activity, 100 Ci/g), and 400 L of barbital buffer (50 mmol/L, pH 8.6, and containing, per liter, 300 mg of 8-anilino-1-naphthalenesulfonic acid, 7.5 g of bovine serum gamma-globulin, and 100 mg of thimerosal) at room temperature for 2 h. Free '251-T4was then separated from bound by adding 2 mL of a 180 g/L polyethylene glycol solution. IT3 was added in place of '251-T4 for the study of 1251-T3binding to the serum.
We first characterized T4 binding protein by use of an immunoprecipitation technique. We incubated 5 tL of the serum or 15 sL (50 pig) of IgG with 25 1zLof I-T4
and 100 sL of the barbital buffer described above for 3 h at room temperature. Then, excess anti-human IgG rabbit serum was added and the mixture was incubated for 20 h at 4 #{176}C. The tubes were centrifuged at 10 000 X g for 5 mmand the radioactivity in the precipitate was counted. The IgG fraction of the serum was prepared by column chromatography on DEAE Sephadex A-50 (9) .
Binding studies with 1251-labeled thyroglobulin as tracer were done in the same buffer we used for '251-T4. We incubated 25 iL of '251-labeled thyroglobulin, 10 zL (10 tg) of IgG, and 100 tL of the barbital buffer at 4 #{176}C for 24 h. Immunoprecipitation was then effected by adding anti-human IgG rabbit serum. Human thyroglobulin, from a goiter of a patient with Graves' disease, was purified by gel chromatography on a 1.5 X 100cm column of Biogel A-5m (Bio-Rad Labs., Richmond, CA 94804) after precipitation with ammonium sulfate in final concentration between 350 and 450 g/L (10). Thyroglobulin was iodinated with 125J by the lactoperoxidase method (11) . The specific activity was 10 to 30 Ci/g.
For analysis ofT4 binding characteristics we used 250 sg (75 giL) of IgG. After adding a tracer dose of '25I-T4 (10 000 cpm), we diluted the incubation mixture to 500 sL with the barbital buffer and incubated for 2 hat room temperature. We separated free '251-T4 from bound in the same manner as described above, with use of polyethylene glycol. We studied the binding of the 125I-T4 derivative used in Amersham's free T4 RIA to the patient's IgG by adding 25 1zLof the derivative to 10 iL (50 zg) of IgG and 100 sL of the barbital buffer. The mixture was incubated at room temperature for 3 h and immunoprecipitated with anti-human IgG rabbit serum.
Anti-thyroglobulin and anti-microsome antibodies were detected by a hemagglutination technique, with commercial kits (Fuji-Zoki Co., Shinjuku-ku, Tokyo 161).
Results
Despite a marked diminution in total T4 concentrations as determined in unextracted sera by RIA with use of polyethylene glycol, the total T4 concentrations as measured with competitive protein binding, in which T4 was extracted by ethanol, were low or borderline-normal (Table 1) . This discrepancy suggested that an abnormal T4 binding protein was present in the patient's serum.
The mean amount of 1251-T4precipitated by the patient's serum in the absence of rabbitanti-T4 antibody in the polyethylene glycol separation technique was 31.5 (SD 1.3)% as compared with the background binding of 4.7 (SD 0.3)% for a control serum. Less than 3% of IT3 was precipitated from either normal serum or the patient's serum. By the doubleantibody method, percentages of 1251T4 bound in the patient's serum and its IgG fraction (50 sg) were 10.8 (SD 1.2)% and 12.5 (SD 0.9)%, respectively, while the percent of '251-T4 precipitated was <3% in both normal serum and its IgG fraction.
When '251-labeled thyroglobulin was used as the tracer, the percentage of the tracer bound to the patient's IgG and a control IgG were 64.0 (SD 2.9)% and 5.5 (SD 0.1)%, respectively. The bound '25I-labeled thyroglobulin was completely displaced by added thyroglobulin, but only 10% of the 125I labeled thyroglobulin could be displaced by T4 (1 sg per tube) . Binding of '25I-T4 to 250 sg of the IgG fraction, as determined by the polyethylene glycol precipitation method, was 67%. From the Scatchard plots of the T4 binding to both the patient's IgG and the anti-T4 serum of the RIA kit, the association constants were calculated as 8.0 X 108 L/mo! and 3.3 X 10 L/mol, respectively. The binding capacities were 6.3 nmol/g of IgG and 2.9 nmoliL of antiserum, respectively. No significant cross reaction with T3 was observed.
We studied the effect of the anti-T4 antibody on the RIA of free T4 by measuring two serially collected sera, which showed a marked discrepancy in total T4 values by RIA (Table   2 ). Values for both free T4, as determined by equilibrium dialysis, and the free thyroxine index of these sera were low or borderline normal. The results obtained with both the Clinical Assays and Damon Diagnostics kits agreed well with these values, when the normal ranges of these assays were takeninto consideration. On the other hand, free T4 values obtained with Amersham's kit were exceedingly high. We suspected the cause of these erroneously high values for free T4 to be direct binding of '251-T4 derivative of the kit to the patient's IgG. When '251-T4 derivative was incubated with IgG and then immunoprecipitated with anti-human IgG rabbit serum, the values for 1251-T4derivative bound to the patient's IgG and to a normal IgG were 38.5 (SD 1.6)% and 4.0 (SD 0.1)%, respectively.
Discussion
In this patient, values for serum T4 obtained by RIA with use of polyethylene glycolto separate the bound and the free T4 were zero or almost so. However, on extraction of the serum with ethanol, low-or borderline-normal concentrations of T4 were found. fashion analogous to a hapten to generate antibodies. The antibody found in the patient showed greater avidity for thyrog!obulin than for T4. However, results of a conventional hemagglutination test for anti-thyrog!obulin were only transiently positive. This finding could be ascribed to the presence of hemagglutination-inhibiting factor such as have been described in autoimmune thyroid disease (12) .Although thyroglobulin antibodies detected by hemagglutination have been found to coexist with iodothyronine binding antibodies in most cases, they are absent in some (13) (14) (15) .
The patient was clinically euthyroid when he was found to have the anti-T4 antibody. Values for both total T4 by competitive protein binding and free T4 by equilibrium dialysis were low-or borderline-normal. However, the values for serum T3 were slightly above normal, and no increase in thyrotropin was observed. This pattern of iodothyronine concentration is known to be present in patients with Graves' disease who are under chronic treatment with antithyroid drugs because of intrathyroid iodine deficiency (16) .
The antibody interfered with a RIA system for measurement of free T4 as well as those for total T4. Of the three free T4 RIAs studied, two gave values equivalent to those by equilibrium dialysis, and compatible with the clinical state of the patient. These are kits in which contact between 125I-T4 and serum binding proteins is avoided by either washing antibody-coated tubes (Clinical Assays) or by microencapsulating the antibody coupled with the tracer (Damon Diagnostics). On the other hand, values for free T4 with Amersham's kit were remarkably affected by the presence of the autoantibody. This kit includes an 1251-T4derivative, which essentially does not bind to the major endogeneous binding proteins in serum but binds normally to antibodies to T4, allowing the determination of free T4 under the presence of binding proteins. The '251-T4 derivative not only was bound by anti-T4 antibodies of the kit, but also by anti-T4 autoantibodies. In the case of this patient, interaction of the labeled derivative with the abnormal binding site would tend to make less derivative available to compete for the solidphase antibody site of the kit, giving the impression of high concentrations of free hormone. Recently, Stockigt et al. (17) reported that, despite its validity with variation in thyroxin-binding globulin, Amersham's kit was influenced by the lower-affinity, high-capacity T4 binding sites in serum such as prealbumin and albumin. The presence of anti-T4 antibody is another clinical situation where the assay results must be interpreted cautiously to avoid a false impression of hyperthyroidism.
Thus, we consider those free T4 RIA systems useful that avoid contact of 1251-T4with binding proteins in the presence of anti-T4 antibodies. As far as such systems are used, RIA of free T4 appears to offer an advantage over the possibly misleading total T4 measurement by RIA.
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